Snyder Douglas B.

Chief Legal OfficerGW PHARMACEUTICALS PLC (GWPH) · full profile →Form 4 · filed May 7, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
12
1 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 5, 2021Disposed to issuer(D)62K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 5, 2021Disposed to issuer(D)10K0
May 5, 2021Disposed to issuer(D)89K0
May 5, 2021Disposed to issuer(D)13K0
May 5, 2021Disposed to issuer(D)150K0
May 5, 2021Disposed to issuer(D)90K0
May 5, 2021Disposed to issuer(D)9K0
May 5, 2021Disposed to issuer(D)47K0
May 5, 2021Disposed to issuer(D)83K0
May 5, 2021Disposed to issuer(D)63K0
May 5, 2021Disposed to issuer(D)73K0
May 5, 2021Disposed to issuer(D)45K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-21-018666) within minutes of acceptance. Every field above traces to the original document. Verify it directly: